AMT raises €14 million to fund Glybera
This article was originally published in Scrip
Executive Summary
Amsterdam Molecular Therapeutics (AMT) has raised €14.3 million in gross proceeds through a private placement. AMT's main shareholders – Advent Venture Partners, Gilde Healthcare Partners, Credit Agricole Private Equity and Forbion Capital Partners –agreed to invest a total of €3.75 million. The rest of the placement was offered to the company's other investors and members of its board. Pursuant to the placement AMT will issue just under 8.5 million new shares for an offer price of €1.70 each.